AP9901581A0 - Therapeutic combinations for musculoskeletal frailty. - Google Patents

Therapeutic combinations for musculoskeletal frailty.

Info

Publication number
AP9901581A0
AP9901581A0 APAP/P/1999/001581A AP9901581A AP9901581A0 AP 9901581 A0 AP9901581 A0 AP 9901581A0 AP 9901581 A AP9901581 A AP 9901581A AP 9901581 A0 AP9901581 A0 AP 9901581A0
Authority
AP
ARIPO
Prior art keywords
compositions
frailty
pyridin
oxo
phenyl
Prior art date
Application number
APAP/P/1999/001581A
Other languages
English (en)
Inventor
Huazhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9901581A0 publication Critical patent/AP9901581A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/1999/001581A 1998-06-16 1999-06-10 Therapeutic combinations for musculoskeletal frailty. AP9901581A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
AP9901581A0 true AP9901581A0 (en) 1999-06-30

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001581A AP9901581A0 (en) 1998-06-16 1999-06-10 Therapeutic combinations for musculoskeletal frailty.

Country Status (29)

Country Link
EP (1) EP1085867A1 (ja)
JP (1) JP2002518328A (ja)
KR (1) KR20010052817A (ja)
CN (1) CN1305378A (ja)
AP (1) AP9901581A0 (ja)
AR (1) AR018868A1 (ja)
AU (1) AU3342099A (ja)
BG (1) BG105128A (ja)
BR (1) BR9911357A (ja)
CA (1) CA2335112A1 (ja)
CO (1) CO5070586A1 (ja)
EA (1) EA200001189A1 (ja)
GT (1) GT199900083A (ja)
HR (1) HRP20000857A2 (ja)
HU (1) HUP0102395A2 (ja)
ID (1) ID26726A (ja)
IL (1) IL139587A0 (ja)
IS (1) IS5727A (ja)
MA (1) MA26648A1 (ja)
NO (1) NO20006381D0 (ja)
OA (1) OA11569A (ja)
PA (1) PA8472101A1 (ja)
PE (1) PE20000633A1 (ja)
PL (1) PL345064A1 (ja)
SK (1) SK18902000A3 (ja)
TN (1) TNSN99118A1 (ja)
UY (1) UY25557A1 (ja)
WO (1) WO1999065488A1 (ja)
ZA (1) ZA993973B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
DK1460969T3 (da) * 2001-11-29 2008-09-01 Gtx Inc Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
CN1305378A (zh) 2001-07-25
EP1085867A1 (en) 2001-03-28
CO5070586A1 (es) 2001-08-28
BR9911357A (pt) 2001-03-13
HUP0102395A2 (hu) 2001-11-28
AR018868A1 (es) 2001-12-12
AU3342099A (en) 2000-01-05
ID26726A (id) 2001-02-01
PE20000633A1 (es) 2000-07-26
HRP20000857A2 (en) 2001-10-31
OA11569A (en) 2004-07-01
IL139587A0 (en) 2002-02-10
UY25557A1 (es) 2001-01-31
EA200001189A1 (ru) 2001-06-25
NO20006381L (no) 2000-12-14
PL345064A1 (en) 2001-11-19
CA2335112A1 (en) 1999-12-23
GT199900083A (es) 2000-12-05
PA8472101A1 (es) 2000-09-29
JP2002518328A (ja) 2002-06-25
TNSN99118A1 (fr) 2005-11-10
SK18902000A3 (sk) 2001-12-03
KR20010052817A (ko) 2001-06-25
WO1999065488A1 (en) 1999-12-23
BG105128A (en) 2001-11-30
IS5727A (is) 2000-11-24
ZA993973B (en) 2000-12-15
MA26648A1 (fr) 2004-12-20
NO20006381D0 (no) 2000-12-14

Similar Documents

Publication Publication Date Title
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
LU91710I2 (fr) Pazopanib, facultativement sous forme d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
WO2000021926A3 (en) 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
IL132763A0 (en) Novel compounds
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
NO990663L (no) Substituerte pyrimidinderivater og deres farmas°ytiske anvendelse
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
AP9901581A0 (en) Therapeutic combinations for musculoskeletal frailty.
NO993027D0 (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
AP9901582A0 (en) Combination therapy for musculoskeletal frailty.
YU75800A (sh) Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
SI1390022T1 (sl) Uporaba 4-(2-fluorofenil)-6-metil-2-(1-piperazinil) tieno-(2,3-D)pirimidina za tretiranje bolečin
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2